ZLAB insider trading
NasdaqGM HealthcareZai Lab Ltd: insider trade history from SEC Form 4 filings.
About Zai Lab Ltd
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd. to develop and commercialize Tumor Treating Fields; Deciphera Pharmaceuticals, LLC to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx BV to develop and commercialize efgartigimod; Turning Point Therapeutics, Inc. to develop and commercialize products containing repotrectinib; Entasis Therapeutics Holdings Inc. to develop and commercialize Durlobactam with Sulbactam; and Karuna Therapeutics, Inc. to develop and commercialize Xanomeline and trospium chloride, as well as strategic collaboration with Pfizer Inc. for Tisotumab Vedotin. The company was incorporated in 2013 and is based in Pudong, China.
Company website: www.zailaboratory.com
ZLAB insider activity at a glance
FilingIQ tracks 589 insider transactions for ZLAB in filings since Jan 20, 2021. The most recent transaction is dated Oct 1, 2026.
Across the full history, 9 open-market purchases
and 317 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on ZLAB insider trades is 51.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest ZLAB Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for ZLAB?
- FilingIQ tracks 589 Form 4 insider transactions for ZLAB (Zai Lab Ltd), covering filings from Jan 20, 2021 onwards. 7 of those are dated within the last 90 days.
- Are ZLAB insiders net buyers or net sellers?
- Across the full Form 4 history for ZLAB, 9 transactions (2%) were open-market purchases and 317 (54%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ZLAB insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is ZLAB in?
- Zai Lab Ltd (ZLAB) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.16B.
Methodology & sources
Every ZLAB insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.